Guanylyl cyclase inhibitor
ODQ is a potent and selective, direct-acting inhibitor of guanylate cyclase (IC50=20 nM). In cerebellar slices ODQ reversibly inhibited cGMP generation in response to endogenous NO or exogenously added NO-donors. ODQ does not inhibit NO-mediated macrophage toxicity (a phenomenon unrelated to cGMP) and does not inhibit particulate guanylyl cyclase or adenylyl cyclase. ODQ is an unique and selective tool to elucidate the physiological importance of the NO-cGMP pathway.
Shipping: Available products typically ship within 24/48h, via priority shipping.
Do you need support? Contact Customer Service or Technical Support.
Online Account
Access or Create Your Account
Product Details
| Appearance |
Off-white to yellow powder. |
|---|---|
| CAS |
41443-28-1 |
| Couple Target |
Guanylyl cyclase |
| Couple Type |
Inhibitor |
| Formula |
C9H5N3O2 |
| MW |
187.2 |
| Purity |
≥98% (TLC) |
| Solubility |
Soluble in DMSO (5mg/ml), ethyl acetate or 100% ethanol (1.2mg/ml); insoluble in water. |
Handling & Storage
| Use/Stability |
As indicated on product label or CoA when stored as recommended. Solutions may decompose slowly. |
|---|---|
| Handling |
Protect from light. |
| Short Term Storage |
+4°C |
| Long Term Storage |
-20°C |
| Shipping |
Ambient Temperature |
| Regulatory Status |
RUO – Research Use Only |
|---|
- Novel analgesic/anti-inflammatory agents: 1,5-Diarylpyrrole nitrooxyethyl sulfides and related compounds as Cyclooxygenase-2 inhibitors containing a nitric oxide donor moiety endowed with vasorelaxant properties: M. Saletti, et al.; Eur. J. Med. Chem. 241, 114615 (2022), Abstract
- Fermented garlic extract decreases blood pressure through nitrite and sGC-cGMP-PKG pathway in spontaneously hypertensive rats: B.M. Park, et al.; J. Funct. Foods 22, 156 (2016), Application(s): Cell culture
- Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling: Lindsey, S. H., Liu, L., et al.; Steroids 81, 99 (2014), Abstract
- Changes in nerve-mediated contractility of the lower urinary tract in a mouse model of premature ageing: Triguero, D., Lafuente-Sanchis, A., et al.; Br. J. Pharmacol. 171, 1687 (2014), Abstract
- Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice: E.P. Schmidt, et al.; Am. J. Physiol. Lung Cell. Mol. Physiol. 295, (2008), Abstract
- Interstitial cells of Cajal in the urethra are cGMP-mediated targets of nitrergic neurotransmission: García-Pascual, A., Sancho, M., et al.; Am. J. Physiol. Renal Physiol. 295, F971 (2008), Abstract
- Genetic overexpression of eNOS attenuates hepatic ischemia-reperfusion injury: Duranski, M. R., Elrod, J. W., et al.; Am. J. Physiol. Heart Circ. Physiol. 291, H2980 (2006), Abstract
- Biphasic neurogenic vasodilatation in the bovine intraocular long posterior ciliary artery: involvement of nitric oxide and an additional unidentified neurotransmitter: Overend, J., Wilson, W. S., et al.; Br. J. Pharmacol. 145, 1001 (2005), Abstract
- Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols: R. Motterlini, et al.; J. Biol. Chem. 275, 13613 (2000), Abstract — Full Text
- Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea: T.L. Hwang, et al.; Br. J. Pharmacol. 125, 1158 (1998), Abstract
- Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles: C.G. Sobey & F.M. Faraci; Stroke 28, 837 (1997), Abstract
- A comparative study of the effects of three guanylyl cyclase inhibitors on the L-type Ca2+ and muscarinic K+ currents in frog cardiac myocytes: N. Abi-Gerges, et al.; Br. J. Pharmacol. 121, 1369 (1997), Abstract
- Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation: L.J. Olson, et al.; Hypertension 29, 254 (1997), Abstract
- Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase: A. Schrammel, et al.; Mol. Pharmacol. 50, 1 (1996), Abstract
- The nitric oxide-cyclic GMP pathway and synaptic plasticity in the rat superior cervical ganglion: E. Southam, et al.; Br. J. Pharmacol. 119, 527 (1996), Abstract
- cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase: M.A. Moro, et al.; PNAS 93, 1480 (1996), Abstract
- Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion: F. Brunner, et al.; FEBS Lett. 376, 262 (1995), Abstract
- Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase: C.L. Boulton, et al.; Neuroscience 69, 699 (1995), Abstract
- Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one: J. Garthwaite, et al.; Mol. Pharmacol. 48, 184 (1995), Abstract
Related Products
| CAS | 38966-21-1 |
|---|---|
| Couple Type | Inhibitor |
| Purity | ≥98% (TLC) |
| Alternative Name | 6-(6-Methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,8-dihydrofuro[3,4-E][1,3]benzodioxol-8-ol, (+)-Decumbensine |
|---|---|
| CAS | 6883-44-9 |
| Purity | ≥98% (HPLC) |
| Alternative Name | (3S,3aR,4R,4aS,8aR,9aS)-4-[(1E)-2-[(2R,6S)-1,6-Dimethyl-2-piperdinyl]ethenyl]decahydro-3-methyl-naphtho[2,3-c]furan-1(3H)-one |
|---|---|
| CAS | 6879-74-9 |
| Couple Type | Inhibitor |
| Purity | ≥98% |
Last modified: May 29, 2024
Datasheet, Manuals, SDS & CofA
Manuals And Inserts
Certificate of Analysis
Please enter the lot number as featured on the product label
SDS
Enzo Life Science provides GHS Compliant SDS
If your language is not available please fill out the SDS request form
Lab Essentials
AMPIVIEW® RNA probes
Enabling Your Projects
GMP Services
Bulk Solutions
Research Travel Grant
Have You Published Using an Enzo Product?